The rationale and design of the APPLAUSE IgAN trial of #iptacopan - a complement inhibitor - in #IgANephropathy - funded by its maker Novartis

Well timed for #NephMadness #IgANephropathy region! With a great #VisualAbstract from @edgarvlermamd

https://www.sciencedirect.com/science/article/pii/S2468024923000505